Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium‐223
- 1 November 2016
- journal article
- review article
- Published by Wiley in The Prostate
- Vol. 77 (3) , 245-254
Abstract
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a Scientific Working Group Meeting on Radium‐223 on September 8, 2016, at The Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center.METHODS: The meeting was attended by 18 investigators with expertise in radium‐223, bone biology, molecular imaging, biomarkers, and prostate cancer clinical trials. The goal of this meeting was to discuss the known and unknown surroundings the therapeutic effects of the bone targeting agent radium‐223, in bone metastatic prostate cancer therapy, and to outline the most critical studies needed to improve the clinical use of this agent.RESULTS: Three major topic areas were discussed: (1) the basic science of radium; (2) immuno‐adjuvant properties of radium therapy; and (3) high impact clinical trials and correlative science.DISCUSSION: This article reviews the major topics discussed at the meeting for the purpose of accelerating studies that will improve the use of radium‐223 in the treatment of prostate cancer patients. Prostate 77:245–254, 2017.Keywords
This publication has 35 references indexed in Scilit:
- Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trialOncotarget, 2016
- The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancerJournal of Experimental & Clinical Cancer Research, 2015
- Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancerThe FASEB Journal, 2015
- Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesScience Translational Medicine, 2014
- Castration-induced bone loss triggers growth of disseminated prostate cancer cells in boneEndocrine-Related Cancer, 2014
- Prostate Cancer Cells Preferentially Home to Osteoblast-rich Areas in the Early Stages of Bone Metastasis: Evidence From In Vivo ModelsJournal of Bone and Mineral Research, 2014
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialThe Lancet Oncology, 2014
- Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone MetastasisJNCI: Journal of the National Cancer Institute, 2013
- Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical RecurrenceClinical Cancer Research, 2009
- Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new boneOncogene, 2007